Detecting low-quality asparaginase for cancer treatment
Point of use detection of low-quality pharmaceutical asparaginase
This study is working on a simple test card to check the quality of a chemotherapy drug called asparaginase, which is important for treating children with blood cancers in sub-Saharan Africa, so they can receive safer and more effective treatment.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Notre Dame NIH-funded |
| Lab location | 1 site (Notre Dame, United States) |
| Project ID | NIH-11093733 on NIH RePORTER |
What this research studies
This research focuses on developing a point-of-use test card, known as the chemoPAD, to ensure the quality of the chemotherapy drug asparaginase in sub-Saharan Africa. The project aims to create reliable screening methods, including tandem mass spectrometry and colorimetric techniques, to identify low-quality formulations of this critical medication. By improving drug quality monitoring, the research seeks to enhance treatment outcomes for children with hematopoietic cancers. Patients will benefit from safer and more effective chemotherapy options.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with hematopoietic malignancies who are receiving asparaginase as part of their treatment.
Not a fit: Patients who are not receiving asparaginase or those with cancers not related to hematopoietic malignancies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved safety and efficacy of chemotherapy treatments for patients with hematopoietic cancers.
How similar studies have performed: Previous research has shown success in developing point-of-use testing methods for drug quality, indicating a promising approach for this project.
Where this research is happening
Notre Dame, United States
- University of Notre Dame — Notre Dame, United States (Active)
Researchers
- Principal investigator: Lieberman, Marya — University of Notre Dame
- Study coordinator: Lieberman, Marya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.